Results 91 to 100 of about 91,007 (250)
ABSTRACT Current prostate cancer detection methods remain limited in non‐invasiveness and specificity, prompting interest in urinary biomarkers such as sarcosine. Here, we report a urine‐powered wearable platform for non‐invasive sarcosine detection as a proof‐of‐concept for decentralized early warning.
Jing Xu +10 more
wiley +1 more source
This study reported renal‐clearable bio‐orthogonal near‐infrared fluorogenic probes (BGRs) that specifically imaging and urinalysis of granzyme B for dynamic evaluation of RCC immunotherapy. BGRs not only differentiate immunotherapeutic responses in orthotopic RCC mice, but also enable sensitive optical urinalysis of granzyme B in clinical specimens ...
Xingyue Yang +9 more
wiley +1 more source
Engineering Microbial Particles for Next‐Generation Biomedical Platforms
Microbe‐derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus‐like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a ...
Yuting Li +7 more
wiley +1 more source
Introduction: Prostate cancer is the second most common cancer in men worldwide, itsincidence has increased by the use of early detection methods such as routine checks,the Prostate Specific Antigen (PSA) and its fractions as a method of screening ...
Benedetti-Padrón Inés +2 more
doaj
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley +1 more source
ABSTRACT Blood‐based liquid biopsies hold transformative potential for non‐invasive cancer management, but current approaches relying on rare circulating tumor components limit their broad clinical utility. Platelets, abundant in blood and mediating diverse cancer‐associated responses, represent a compelling yet largely unexplored alternative.
Yan Ma +28 more
wiley +1 more source
A novel resistance mechanism is mediated through phagocytosis of cancer cells by AR+ TAMs. This process, dependent on ANXA2, enables macrophages to acquire AR protein from engulfed tumor cells. The internalized AR translocates into the macrophage nucleus, where it binds directly to the IL‐6 promoter, augmenting IL‐6 transcription and secretion ...
Yong Luo +13 more
wiley +1 more source
Chao Peng, Jun Zhang, Jianquan Hou Department of Urology, First Affiliated Hospital of Soochow University, Suzhou 215006, China Background: Prognosis for intermediate-risk prostate cancer (PCa) remains variable; therefore, we aimed to investigate high ...
Peng C, Zhang J, Hou JQ
doaj
Engineered extracellular vesicles displaying Ephrin‐B2 selectively target Ephrin‐B4–expressing ovarian cancer cells, enabling precise delivery in patient‐derived models. This scalable bio‐manufacturing platform reveals a versatile strategy to exploit Ephrin signaling for highly specific therapeutic payload delivery and motivates exploration of tailored
Nihar Godbole +17 more
wiley +1 more source
IGF2BP1‐mediated m6A stabilization sustains SMC1A expression, enabling cohesin‐associated chromatin regulation of Nestin in hepatocellular carcinoma. This work reveals an epitranscriptomic‐chromatin‐cytoskeletal regulatory axis linked to malignant phenotypes and identifies SMC1A as a biologically relevant vulnerability in HCC.
Zhenxiang Peng +7 more
wiley +1 more source

